Optical voidness quinazoline compound
A compound, quinazoline technology, applied in the fields of drug combination, organic chemistry, skin diseases, etc., can solve the problem of no optically pure isomer research, and achieve the effect of excellent anti-tumor activity
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Publication Date
- 2012-02-08
Abstract
Description
technical field The invention relates to an optically pure quinazoline compound, a pharmaceutical composition containing a therapeutically effective amount of the compound, and its preparation for treating diseases related to the regulation of c-erbB-2 and / or EGF-R protein tyrosine kinase activity use in medicines. Background technique Protein tyrosine kinases catalyze the phosphorylation of specific tyrosine residues in various proteins involved in the regulation of cell growth and differentiation. Protein tyrosine kinases can be broadly classified as receptor (eg EGFr, c-erbB-2, c-met, tie-2, PDGFr, FGFr) or non-receptor (eg c-src, lck, zap70) kinases. Inappropriate or uncontrolled activation of many of these kinases, i.e. aberrant protein tyrosine kinase activity e.g. by overexpression or mutation, has been shown to lead to uncontrolled cellular production. Abnormal activities of protein tyrosine kinases, such as c-erbB-2, c-src, c-met, EGFr, PDGFr, are associated with...
Examples
preparation example 1
preparation example 2
preparation example 3